← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
MIN
MFS INTERMEDIATE INCOME TRUST
Valuation N/A
Unknown
Price$2.33
Model IV—
P/IV—
Limited data — see page
MINE
MAYFAIR GOLD CORP.
Valuation N/A
Basic Materials
Price$3.05
Model IV—
P/IV—
Limited data — see page
MIR
Mirion Technologies, Inc.
Valuation N/A
Healthcare Risk 38 · Moderate
Price$15.98
Model IV—
P/IV—
Market implies +33.9%/yr vs model +10.6% · above model
MIRA
MIRA PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.77
Model IV—
P/IV—
Limited data — see page
MIST
Milestone Pharmaceuticals Inc.
Valuation N/A
Healthcare Risk 52 · Elevated
Price$0.93
Model IV—
P/IV—
Limited data — see page
MIY
BLACKROCK MUNIYIELD MICHIGAN QUALITY FUND, INC.
Valuation N/A
Unknown
Price$12.07
Model IV—
P/IV—
Limited data — see page
MKDW
MKDWELL Tech Inc.
Valuation N/A
Technology Risk 39 · Moderate
Price$7.75
Model IV—
P/IV—
Market implies +25.1%/yr vs model +2.0% · above model
MKLY
McKinley Acquisition Corp
Valuation N/A
Financial Services
Price$10.25
Model IV—
P/IV—
Limited data — see page
MKLYR
McKinley Acquisition Corp
Valuation N/A
Financial Services
Price$0.27
Model IV—
P/IV—
Limited data — see page
MLAA
Mountain Lake Acquisition Corp. II
Valuation N/A
Financial Services
Price$10.01
Model IV—
P/IV—
Limited data — see page
MLAC
Mountain Lake Acquisition Corp.
Valuation N/A
Financial Services
Price$3.12
Model IV—
P/IV—
Limited data — see page
MLACR
Mountain Lake Acquisition Corp.
Valuation N/A
Financial Services
Price$0.28
Model IV—
P/IV—
Limited data — see page
MLEC
Moolec Science SA
Valuation N/A
Consumer Defensive Risk 40 · Elevated
Price$7.03
Model IV—
P/IV—
Limited data — see page
MLP
MAUI LAND & PINEAPPLE CO INC
Valuation N/A
Real Estate Risk 40 · Elevated
Price$16.29
Model IV—
P/IV—
Market implies +39.1%/yr vs model +11.8% · above model
MLR
MILLER INDUSTRIES INC /TN/
Valuation N/A
Consumer Cyclical Risk 32 · Moderate
Price$54.29
Model IV—
P/IV—
Market implies +29.4%/yr vs model +4.1% · above model
MLSS
MILESTONE SCIENTIFIC INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.44
Model IV—
P/IV—
Market implies +28.1%/yr vs model +2.0% · above model
MLTX
MoonLake Immunotherapeutics
Valuation N/A
Healthcare Risk 31 · Moderate
Price$12.20
Model IV—
P/IV—
Limited data — see page
MLYS
Mineralys Therapeutics, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$28.20
Model IV—
P/IV—
Limited data — see page
MMA
MIXED MARTIAL ARTS GROUP LTD
Valuation N/A
Technology Risk 33 · Moderate
Price$0.42
Model IV—
P/IV—
Limited data — see page
MMD
NYLI MacKay DefinedTerm Muni Opportunities Fund
Valuation N/A
Unknown
Price$14.16
Model IV—
P/IV—
Limited data — see page
MMED
MiniMed Group, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$22.50
Model IV—
P/IV—
Limited data — see page
MMT
MFS MULTIMARKET INCOME TRUST
Valuation N/A
Unknown
Price$4.32
Model IV—
P/IV—
Limited data — see page
MMTX
Miluna Acquisition Corp
Valuation N/A
Financial Services Risk 37 · Moderate
Price$10.18
Model IV—
P/IV—
Limited data — see page
MMTXW
Miluna Acquisition Corp
Valuation N/A
Financial Services Risk 42 · Elevated
Price$0.11
Model IV—
P/IV—
Limited data — see page
MMYT
MakeMyTrip Ltd
Valuation N/A
Industrials
Price$50.09
Model IV—
P/IV—
Limited data — see page
MNOV
MEDICINOVA INC
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.81
Model IV—
P/IV—
Market implies +68.2%/yr vs model +2.0% · above model
MNPR
Monopar Therapeutics
Valuation N/A
Healthcare Risk 37 · Moderate
Price$104.33
Model IV—
P/IV—
Limited data — see page
MNSO
MINISO Group Holding Ltd
Valuation N/A
Consumer Cyclical Risk 32 · Moderate
Price$9.07
Model IV—
P/IV—
Limited data — see page
MNTS
Momentus Inc.
Valuation N/A
Consumer Cyclical Risk 37 · Moderate
Price$4.04
Model IV—
P/IV—
Market implies +66.1%/yr vs model +8.0% · above model
MNY
MoneyHero Ltd
Valuation N/A
Technology
Price$0.76
Model IV—
P/IV—
Limited data — see page
MNYWW
MoneyHero Ltd
Valuation N/A
Technology
Price$0.03
Model IV—
P/IV—
Limited data — see page
MOB
Mobilicom Ltd
Valuation N/A
Industrials Risk 27 · Moderate
Price$4.79
Model IV—
P/IV—
Limited data — see page
MOBBW
Mobilicom Ltd
Valuation N/A
Industrials Risk 42 · Elevated
Price$1.65
Model IV—
P/IV—
Limited data — see page
MOBI
Mobia Medical, Inc.
Valuation N/A
Healthcare Risk 54 · Elevated
Price$10.77
Model IV—
P/IV—
Limited data — see page
MOD
MODINE MANUFACTURING CO
Valuation N/A
Consumer Cyclical Risk 43 · Elevated
Price$189.30
Model IV—
P/IV—
Market implies +43.2%/yr vs model +8.0% · above model
MODD
Modular Medical, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$2.41
Model IV—
P/IV—
Limited data — see page
MOGU
MOGU Inc.
Valuation N/A
Technology Risk 26 · Moderate
Price$1.88
Model IV—
P/IV—
Market implies +81.1%/yr vs model +2.0% · above model
MOLN
MOLECULAR PARTNERS AG
Valuation N/A
Healthcare Risk 50 · Elevated
Price$4.18
Model IV—
P/IV—
Limited data — see page
MOVE
Corvex, Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$11.13
Model IV—
P/IV—
Market implies +58.9%/yr vs model +15.0% · above model
MP
MP Materials Corp. / DE
Valuation N/A
Basic Materials Risk 44 · Elevated
Price$50.51
Model IV—
P/IV—
Market implies +56.0%/yr vs model +0.0% · above model
MPA
BLACKROCK MUNIYIELD PENNSYLVANIA QUALITY FUND
Valuation N/A
Unknown
Price$10.40
Model IV—
P/IV—
Limited data — see page
MPLT
MapLight Therapeutics, Inc.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$13.00
Model IV—
P/IV—
Limited data — see page
MPV
BARINGS PARTICIPATION INVESTORS
Valuation N/A
Unknown
Price$17.19
Model IV—
P/IV—
Limited data — see page
MPWR
MONOLITHIC POWER SYSTEMS INC
Valuation N/A
Technology Risk 36 · Moderate
Price$1,142.46
Model IV—
P/IV—
Market implies +33.6%/yr vs model +23.3% · above model
MQY
BLACKROCK MUNIYIELD QUALITY FUND, INC.
Valuation N/A
Unknown
Price$10.32
Model IV—
P/IV—
Limited data — see page
MRAM
EVERSPIN TECHNOLOGIES INC.
Valuation N/A
Technology Risk 55 · Elevated
Price$16.22
Model IV—
P/IV—
Market implies +42.3%/yr vs model +2.0% · above model
MRCY
MERCURY SYSTEMS INC
Valuation N/A
Technology Risk 38 · Moderate
Price$80.61
Model IV—
P/IV—
Market implies +29.2%/yr vs model +3.4% · above model
MREO
Mereo BioPharma Group plc
Valuation N/A
Healthcare Risk 34 · Moderate
Price$0.28
Model IV—
P/IV—
Market implies +36.1%/yr vs model +15.0% · above model
MRLN
Merlin, Inc.
Valuation N/A
Technology Risk 40 · Elevated
Price$3.05
Model IV—
P/IV—
Limited data — see page
MRM
Medirom Healthcare Technologies Inc.
Valuation N/A
Consumer Cyclical Risk 42 · Elevated
Price$0.83
Model IV—
P/IV—
Limited data — see page
MRNA
Moderna, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$143.97
Model IV—
P/IV—
Market implies +73.3%/yr vs model +2.0% · above model
MRNO
Murano Global Investments Plc
Valuation N/A
Consumer Cyclical Risk 64 · High
Price$0.19
Model IV—
P/IV—
Limited data — see page
MRNOW
Murano Global Investments Plc
Valuation N/A
Consumer Cyclical Risk 62 · High
Price$0.01
Model IV—
P/IV—
Limited data — see page
MRT
Marti Technologies, Inc.
Valuation N/A
Industrials Risk 67 · High
Price$2.07
Model IV—
P/IV—
Market implies +144.4%/yr vs model +2.0% · above model
MRVI
MARAVAI LIFESCIENCES HOLDINGS, INC.
Valuation N/A
Healthcare Risk 48 · Elevated
Price$6.53
Model IV—
P/IV—
Market implies +55.5%/yr vs model +2.0% · above model
MRX
Marex Group plc
Valuation N/A
Financial Services Risk 41 · Elevated
Price$73.00
Model IV—
P/IV—
Limited data — see page
MS
MORGAN STANLEY
Valuation N/A
Financial Services Risk 40 · Elevated
Price$214.38
Model IV—
P/IV—
Market implies +35.7%/yr vs model +4.3% · above model
MSAI
MultiSensor AI Holdings, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$4.81
Model IV—
P/IV—
Market implies +99.1%/yr vs model +2.0% · above model
MSBT
Morgan Stanley Bitcoin Trust
Valuation N/A
Financial Services
Price$22.16
Model IV—
P/IV—
Limited data — see page
MSC
STUDIO CITY INTERNATIONAL HOLDINGS Ltd
Valuation N/A
Consumer Cyclical Risk 70 · High
Price$1.77
Model IV—
P/IV—
Limited data — see page